Cochlear is the global leader in implantable hearing solutions with products including cochlear implants, bone conduction implants, and acoustic implants. Cochlear commenced operations in 1981 as part of the Nucleus group and in 1995, listed on the Australian Securities Exchange.
Cochlear aims to support cochlear implantation becoming the standard of care for people with severe to profound hearing loss and provide bone conduction implants for patients with the conductive hearing loss, mixed hearing loss, and single-sided deafness. The Company has provided more than 550,000 implant solutions to recipients who benefit from one – or two – of the Company’s implantable devices. Whether these hearing solutions were implanted today or many years ago, Cochlear provides new technologies and innovations for all recipients. Cochlear invests more than $160 million each year in R&D and currently participates in over 100 collaborative research programs worldwide.
Cochlear’s global headquarters are on the campus of Macquarie University in Sydney, with regional headquarters in the Asia Pacific, Europe and the Americas. Cochlear has a deep geographical reach, selling in over 100 countries, with a direct presence in over 30 countries and a global workforce of over 3,500 employees.